首页> 外文期刊>Journal of Medicinal Chemistry >Synthesis and biological evaluation of novel pyridazinone-based alpha(4) integrin receptor antagonists
【24h】

Synthesis and biological evaluation of novel pyridazinone-based alpha(4) integrin receptor antagonists

机译:新型基于哒嗪酮的α(4)整合素受体拮抗剂的合成及生物学评价

获取原文
获取原文并翻译 | 示例
           

摘要

A novel series of pyridazinone-functionalized phenylalanine analogues was prepared and evaluated for inhibition of cellular adhesion mediated by alpha(4)beta(1)/VCAM-1 and alpha(4)beta(7)/MAdCAM-1 interactions. Concise syntheses were developed and applied for exploration of structure-activity relationships pertaining to the pyridazinone ring as well as the N-acyl phenylalanine scaffold. Potent dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) were generated from an amide subseries; antagonists selective for alpha(4)beta(7) were identified from urea and carbamate-based subseries. The pharmacokinetic properties of selected members of the series have been determined in rats and demonstrate that the use of ester prodrugs and alterations to the amide linkage can lead to improved oral bioavailability in this series. An alpha(4),beta(7)-selective member of the carbamate subseries (36c), upon oral admininstration, demonstrated in vivo efficacy in the mouse DSS colitis model.
机译:制备了一系列新的哒嗪酮功能化的苯丙氨酸类似物,并评估了其对由alpha(4)beta(1)/ VCAM-1和alpha(4)beta(7)/ MAdCAM-1相互作用介导的细胞粘附的抑制作用。开发了简明的合成方法,并将其用于探索与哒嗪酮环以及N-酰基苯基丙氨酸支架有关的构效关系。有效的双重拮抗剂的alpha(4)beta(1)和alpha(4)beta(7)是从一个酰胺亚系列产生的。从基于尿素和氨基甲酸酯的亚系列中鉴定出对α(4)beta(7)有选择性的拮抗剂。已在大鼠中确定了该系列中选定成员的药代动力学特性,证明了使用酯类前药和改变酰胺键可以提高该系列中的口服生物利用度。口服给药后,氨基甲酸酯亚系列(36c)的alpha(4),beta(7)选择性成员在小鼠DSS结肠炎模型中显示出体内功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号